English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA new study by researchers at Case Western Reserve University revealed that the progression of Alzheimer’s disease (AD) can be slowed by suppressing a specific protein in the brain that causes corrosion.
Tag: Leqembi
Lecanemab FDA Approval: U-Mich Alzheimer’s disease expert available and quote #lecanemab
On July 6, the U.S. Food and Drug Administration granted full approval to the new Alzheimer’s disease drug lecanemab (brand name Leqembi). The medication was granted accelerated approval in January. With the landmark decision, University of Michigan Health, Michigan Medicine,…
UTHealth Houston expert available to discuss anti-Alzheimer’s drug Leqembi ahead of FDA decision
The FDA has granted Priority Review to the anti-Alzheimer’s drug Leqembi for the traditional approval application, with required action from the agency by July 6, 2023. Paul E. Schulz, MD, professor of neurology and director of the Neurocognitive Disorders Center with McGovern…
Ahead of Lecanemab FDA Decision: University of Michigan #Alzheimers expert available for interview
The U.S. Food and Drug Administration is considering full approval of the new Alzheimer’s disease drug Lecanemab (brand name Leqembi), with a decision expected by July 6. University of Michigan Health, Michigan Medicine, has an expert available to talk about…
UTHealth Houston expert available to discuss VA’s coverage of Alzheimer’s drug
Paul E. Schulz, MD, neurologist with UTHealth Houston and Memorial Hermann, is available over the next few days to comment on recent news that the Veterans Health Administration will provide coverage for Leqembi, which recently received accelerated approval from the…